The TOMMORROW study was a unique phase III global study of 3500 healthy volunteers at risk for developing mild cognitive impairment (MCI) due to Alzheimer’s disease within the next 5 years.  The two primary goals were to qualify a biomarker and evaluate the efficacy of a compound in delaying the onset of MCI.  Learn more about how VeraSci efficiently and effectively supported the study, including:

  • Training 1200+ raters
  • Providing linguistic and cultural adaptation for study materials
  • Centrally scoring assessments
  • Tracking and reporting on rater performance


Click Here to Visit the Full VeraSci Site